2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-14754R
    Salirasib (Standard)
    		Inhibitor
    Salirasib (Standard) is the analytical standard of Salirasib. This product is intended for research and analytical applications. Salirasib is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.
    Salirasib (Standard)
  • HY-132129
    SOS1-IN-2
    		Inhibitor
    SOS1-IN-2 (Compound 1-1) is an inhibitor of SOS1 with an IC50 value of 5 nM. SOS1-IN-2 can be used in tumor research.
    SOS1-IN-2
  • HY-13991A
    (S)-CCG-1423
    (S)-CCG-1423 is an inhibitor of Rho signaling that blocks the nuclear import of MRTF-A. (S)-CCG-1423 reduces the nuclear accumulation of MRTF-A and improves glucose uptake and tolerance in insulin-resistance mice in vivo. (S)-CCG-1423 exhibits higher inhibition activity than the SR- and the R-isomers of CCG-1423 (HY-13991). (S)-CCG-1423 can be used for the research of cancer and diabetes.
    (S)-CCG-1423
  • HY-145019
    KRAS G12C inhibitor 22
    		Inhibitor
    KRAS G12C inhibitor 22 is a KRAS G12C inhibitor extracted from patent WO2021219072A1, example 120.
    KRAS G12C inhibitor 22
  • HY-168847
    INCB159020
    		Inhibitor
    INCB159020 is an orally active KRAS G12D inhibitor with a KRAS G12D SPR value of 2.2 nM. INCB159020 has antitumor activity.
    INCB159020
  • HY-139403
    MRTX849 ethoxypropanoic acid
    		Antagonist
    MRTX849 ethoxypropanoic acid incorporates a ligand for KRAS G12C, and a PROTAC linker. MRTX849 ethoxypropanoic acid can be used in the synthesis of PROTAC LC-2 (HY-137516). LC-2 is a potent and first-in-class PROTAC capable of degrading endogenous KRAS G12C (IC50s between 0.25 and 0.76 μM).
    MRTX849 ethoxypropanoic acid
  • HY-168893
    K882
    		Inhibitor
    K882 (Compound 4e) is a Src inhibitor, with KD of 0.315 μM. K882 induces Apoptosis. K882 inhibits XIAP and Survivin. K882 inhibits the activation of PI3K/Akt/mTOR, Jak1/Stat3, Ras/MAPK signaling pathways. K882 shows anti-tumor activity against non-small cell lung cancer.
    K882
  • HY-115562
    Dorrigocin A
    		Inhibitor
    Dorrigocin A is an analog of Migrastatin (HY-121452). Dorrigocin A can inhibit the carboxymethyltransferase involved in Ras processing and reverse the morphology of ras-transformed NIH/3T3 cells. Dorrigocin A is promising for research of anti-cancer and anti-arthritis agents.
    Dorrigocin A
  • HY-162968
    MRTF-A-IN-1
    		Inhibitor
    MRTF-A-in-1 (Compound 14) is MRTF-A inhibitor. MRTF-A-in-1 can inhibit cell proliferation and induce HCC cell aging.
    MRTF-A-IN-1
  • HY-151566
    Antifungal agent 46
    		Inhibitor
    Antifungal agent 46 (compound 2f) is a potent antifungal agent. Antifungal agent 46 prevents Ras signaling by inhibiting protein farnesyltransferase.
    Antifungal agent 46
  • HY-162442
    pan-KRAS-IN-9
    		Inhibitor
    pan-KRAS-IN-9 (Compound 52) is an inhibitor for in human tumor mutated genes KRAS, which inhibits proliferation of KRAS mutated cells AsPC-1 (G12D mutant) and SW480 (G12V mutant) with IC50 of 0.24 and 0.30 nM, respectively.
    pan-KRAS-IN-9
  • HY-173250
    YN14-H
    		Degrader
    YN14-H is a PROTAC degrader targeting KRASG12C. YN14-H inhibits cell growth in NCI-H358 and MIA PaCa-2 cells (IC50 values of 0.042, 0.021 μM, DC50 values of 28.9, 18.1 nM, respectively). YN14-H significantly induces apoptosis and inhibits migration. YN14-H demonstrates favorable pharmacokinetic properties and excellent antitumor activity in vivo. (Structure Note: Pink: target protein ligand (HY-173252); Blue: E3 ligase ligand (HY-125905); Black: linker (HY-Y0840); E3 ligase ligand + linker (HY-173253).
    YN14-H
  • HY-144657
    (4S)-PROTAC SOS1 degrader-1
    		Inhibitor
    (4S)-PROTAC SOS1 degrader-1 is a potent PROTAC SOS1 degrader. (4S)-PROTAC SOS1 degrader-1 decreases the expression of pERK and RAS-GTP level in a dose-dependent manner. (4S)-PROTAC SOS1 degrader-1 significantly inhibits the tumor growth in vivo.
    (4S)-PROTAC SOS1 degrader-1
  • HY-131598
    6-Thio-GTP
    		Inhibitor
    6-Thio-GTP is an analogue of GTP, and a metabolite of an immunosuppressive drug, Azathioprine (HY-B0256).
    6-Thio-GTP
  • HY-164802
    Pan-RAS-IN-7
    		Inhibitor
    Pan-RAS-IN-7 (Compound D101) is a pan RAS inhibitor that can be used for the synthesis of ADCs. Pan-RAS-IN-7 can be utilized in cancer research.
    Pan-RAS-IN-7
  • HY-176419
    KRAS inhibitor-42
    		Inhibitor
    KRAS inhibitor-42 (compound 8) is a potent USP7 inhibitor. KRAS inhibitor-42 has high affinity against GDP-bound KRASG12D with a Ki of 2.7 μM.
    KRAS inhibitor-42
  • HY-112493
    KRas G12C inhibitor 3
    		Inhibitor
    KRas G12C inhibitor 3 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
    KRas G12C inhibitor 3
  • HY-172221
    SOS1-IN-18
    		Inhibitor
    SOS1-IN-18 (Compound 8) is the inhibitor for Son of Sevenless 1 protein (SOS1) with a KD of 2.6 nM, and inhibits SOS1-KRAS G12C interaction with an IC50 of 3.4 nM. SOS1-IN-18 inhibits the phosphorylation of ERK in H358 with an IC50 of 31 nM, inhibits the proliferation of H358 with an IC50 of 5 nM.
    SOS1-IN-18
  • HY-168678
    PROTAC K-Ras Degrader-6
    		Inhibitor
    pan-KRAS degrader 5 (compound 102) is a potent cereblon-based KRAS PROTAC degrader, with a DC50 of <100 nM. pan-KRAS degrader 5 shows anticancer effects. (Pink: ligand for target protein (HY-168679); Black: linker (HY-168670); Blue: E3 ligase ligand (HY-W580113)).
    PROTAC K-Ras Degrader-6
  • HY-149847
    JH530
    JH530 is an effective methuosis inducer that inhibits the triple-negative breast cancer (TNBC) cells proliferation by causing intracellular complete vacuolization. JH530 has anti-tumor activity and can be used for cancer research.
    JH530
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.